355 related articles for article (PubMed ID: 16537880)
1. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
4. Clinical and radiological features of Mycobacterium kansasii and other NTM infections.
Matveychuk A; Fuks L; Priess R; Hahim I; Shitrit D
Respir Med; 2012 Oct; 106(10):1472-7. PubMed ID: 22850110
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium kansasii pulmonary diseases in Korea.
Yim JJ; Park YK; Lew WJ; Bai GH; Han SK; Shim YS
J Korean Med Sci; 2005 Dec; 20(6):957-60. PubMed ID: 16361804
[TBL] [Abstract][Full Text] [Related]
6. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London.
Davies BS; Roberts CH; Kaul S; Klein JL; Milburn HJ
Scand J Infect Dis; 2012 Nov; 44(11):815-9. PubMed ID: 23078529
[TBL] [Abstract][Full Text] [Related]
7. [Nontuberculous mycobacterial infections of the lung].
Latshang TD; Lo Cascio CM; Russi EW
Ther Umsch; 2011 Jul; 68(7):402-6. PubMed ID: 21728159
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
[TBL] [Abstract][Full Text] [Related]
9. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
10. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.
Bakuła Z; Modrzejewska M; Pennings L; Proboszcz M; Safianowska A; Bielecki J; van Ingen J; Jagielski T
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437627
[TBL] [Abstract][Full Text] [Related]
11. [Distribution and drug resistance of nontuberculous
Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
[No Abstract] [Full Text] [Related]
12. Treatment of pulmonary disease caused by Mycobacterium kansasii.
Huang HL; Lu PL; Lee CH; Chong IW
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S51-S57. PubMed ID: 32505588
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
[TBL] [Abstract][Full Text] [Related]
14. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection.
Cattamanchi A; Nahid P; Marras TK; Gotway MB; Lee TJ; Gonzalez LC; Morris A; Webb WR; Osmond DH; Daley CL
Chest; 2008 Apr; 133(4):875-80. PubMed ID: 18263685
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and epidemiological study of disease caused by Mycobacterium kansasii in the metropolitan area of Bilbao, Spain].
Leal Arranz MV; Gaafar A; Unzaga Barañano MJ; Crespo Notario JA; Cisterna Cáncer R; García Cebrián F
Arch Bronconeumol; 2005 Apr; 41(4):189-96. PubMed ID: 15826528
[TBL] [Abstract][Full Text] [Related]
16. Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection.
Shitrit D; Peled N; Bishara J; Priess R; Pitlik S; Samra Z; Kramer MR
Respir Med; 2008 Nov; 102(11):1598-603. PubMed ID: 18619826
[TBL] [Abstract][Full Text] [Related]
17. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
[TBL] [Abstract][Full Text] [Related]
18. [A case of pulmonary Mycobacterium kansasii infection with pleural effusion, distinguished from pulmonary tuberculosis].
Kimura Y; Kurosawa T; Hosaka K
Kekkaku; 2014 Sep; 89(9):737-41. PubMed ID: 25730945
[TBL] [Abstract][Full Text] [Related]
19. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of Mycobacterium kansasii infection from Mycobacterium tuberculosis infection: comparison of clinical features, radiological appearance, and outcome.
Shitrit D; Priess R; Peled N; Bishara G; Shlomi D; Kramer MR
Eur J Clin Microbiol Infect Dis; 2007 Oct; 26(10):679-84. PubMed ID: 17629758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
